Legal & General Group Plc Purchases 3,117 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legal & General Group Plc increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 151,550 shares of the medical equipment provider's stock after purchasing an additional 3,117 shares during the quarter. Legal & General Group Plc owned 0.22% of Lantheus worth $13,558,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of Lantheus during the 4th quarter valued at about $36,183,000. Swedbank AB boosted its holdings in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after purchasing an additional 385,000 shares during the last quarter. Keybank National Association OH bought a new stake in Lantheus in the 4th quarter worth approximately $27,526,000. Norges Bank purchased a new stake in Lantheus during the 4th quarter valued at $26,189,000. Finally, Wellington Management Group LLP bought a new position in shares of Lantheus during the 4th quarter valued at $20,022,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 in the last ninety days. Corporate insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LNTH shares. JMP Securities reissued a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, B. Riley dropped their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Trading Up 0.8 %

LNTH traded up $0.80 on Friday, hitting $101.32. 430,521 shares of the company's stock traded hands, compared to its average volume of 954,003. Lantheus Holdings, Inc. has a one year low of $61.47 and a one year high of $126.89. The company's 50 day simple moving average is $95.00 and its 200-day simple moving average is $95.55. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of 16.86 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.